Personal information

Websites & social links

LinkedIn

Activities

Collapse all

Works (13)

Postmortem toxicology findings from the Camden Opioid Research Initiative.

PloS one
2023-11-01 | Journal article
DOI: 10.1371/journal.pone.0292674
PMID: 37910493
PMC: PMC10619848
Contributors: Dara Kusic; Heil J; Zajic S; Brangan A; Dairo O; Heil S; Feigin G; Kacinko S; Buono RJ; Ferraro TN et al.
Source: Self-asserted source
Andrew Brangan

Yield of Familial Hypercholesterolemia Genetic and Phenotypic Diagnoses After Electronic Health Record and Genomic Data Screening

Journal of the American Heart Association
2023-07-04 | Journal article
DOI: 10.1161/JAHA.123.030073
Contributors: Samuel S. Gidding; H. Lester Kirchner; Andrew Brangan; William Howard; Melissa A. Kelly; Kelly D. Myers; Kelly M. Morgan; Matthew T. Oetjens; Timothy C. Shuey; David Staszak et al.
Source: check_circle
Crossref

Designing implementation strategies to improve identification, cascade testing, and management of families with familial hypercholesterolemia: An intervention mapping approach.

Frontiers in health services
2023-04-28 | Journal article
DOI: 10.3389/frhs.2023.1104311
PMID: 37188259
PMC: PMC10175779
Contributors: Jones LK; Calvo EM; Campbell-Salome G; Walters NL; Brangan A; Rodriguez G; Ahmed CD; Morgan KM; Gidding SS; Williams MS et al.
Source: Self-asserted source
Andrew Brangan

Optimizing communication strategies and designing a comprehensive program to facilitate cascade testing for familial hypercholesterolemia.

BMC health services research
2023-04-05 | Journal article
DOI: 10.1186/s12913-023-09304-y
PMID: 37020233
PMC: PMC10074725
Contributors: Gemme Campbell-Salome; Jones LK; Walters NL; Morgan KM; Brangan A; Ladd IG; McGowan MP; Wilemon K; Schmidlen TJ; Simmons E et al.
Source: Self-asserted source
Andrew Brangan

Facilitating family communication of familial hypercholesterolemia genetic risk: Assessing engagement with innovative chatbot technology from the IMPACT-FH study.

PEC innovation
2023-02-04 | Journal article
DOI: 10.1016/j.pecinn.2023.100134
PMID: 37214500
PMC: PMC10194298
Contributors: Walters NL; Lindsey-Mills ZT; Brangan A; Savage SK; Schmidlen TJ; Morgan KM; Tricou EP; Betts MM; Jones LK; Sturm AC et al.
Source: Self-asserted source
Andrew Brangan

Patient Perceptions and Potential Utility of Pharmacogenetic Testing in Chronic Pain Management and Opioid Use Disorder in the Camden Opioid Research Initiative

Pharmaceutics
2022-09-03 | Journal article
DOI: 10.3390/pharmaceutics14091863
Part of ISSN: 1999-4923
Contributors: Andrew Brangan
Source: Self-asserted source
Andrew Brangan

Patient Experiences Align with The Familial Hypercholesterolemia Global Call to Action

American Journal of Preventive Cardiology
2022-04 | Journal article
DOI: 10.1016/j.ajpc.2022.100344
Part of ISSN: 2666-6677
Source: Self-asserted source
Andrew Brangan

Motivating cascade testing for familial hypercholesterolemia: applying the extended parallel process model for clinician communication

Translational Behavioral Medicine
2022-04-16 | Journal article
DOI: 10.1093/tbm/ibac018
Part of ISSN: 1869-6716
Part of ISSN: 1613-9860
Source: Self-asserted source
Andrew Brangan

Acceptability, Appropriateness, and Feasibility of Automated Screening Approaches and Family Communication Methods for Identification of Familial Hypercholesterolemia: Stakeholder Engagement Results from the IMPACT-FH Study

Journal of Personalized Medicine
2021-06-21 | Journal article
DOI: 10.3390/jpm11060587
Contributors: Laney Jones; Nicole Walters; Andrew Brangan; Catherine Ahmed; Michael Gatusky; Gemme Campbell-Salome; Ilene Ladd; Amanda Sheldon; Samuel Gidding; Mary McGowan et al.
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Developing and Optimizing Innovative Tools to Address Familial Hypercholesterolemia Underdiagnosis

Circulation: Genomic and Precision Medicine
2021-02 | Journal article
DOI: 10.1161/CIRCGEN.120.003120
Contributors: Gemme Campbell-Salome; Laney K. Jones; Max F. Masnick; Nephi A. Walton; Catherine D. Ahmed; Adam H. Buchanan; Andrew Brangan; Edward D. Esplin; David G. Kann; Ilene G. Ladd et al.
Source: check_circle
Crossref

Common Treatment, Common Variant: Evolutionary Prediction of Functional Pharmacogenomic Variants

Journal of Personalized Medicine
2021-02-16 | Journal article
DOI: 10.3390/jpm11020131
Part of ISSN: 2075-4426
Source: Self-asserted source
Andrew Brangan

The Genomics of Opioid Addiction Longitudinal Study (GOALS): study design for a prospective evaluation of genetic and non-genetic factors for development of and recovery from opioid use disorder.

BMC medical genomics
2021-01-07 | Journal article
DOI: 10.1186/s12920-020-00837-3
PMID: 33413350
PMC: PMC7792024
Source: Self-asserted source
Andrew Brangan

Individuals with CYP2C8 and CYP2C9 reduced metabolism haplotypes self-adjusted ibuprofen dose in the Coriell Personalized Medicine Collaborative.

Pharmacogenetics and genomics
2019-04-01 | Journal article
DOI: 10.1097/fpc.0000000000000364
PMID: 30562214
Source: Self-asserted source
Andrew Brangan
How many people are using ORCID?